# GEA-01 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gea-01

> GEA-01, sponsored by Jazz Pharmaceuticals plc (JAZZ): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GEA-01 |
| Codes | GEA-01 |
| Sponsor | Jazz Pharmaceuticals plc (JAZZ) https://sec-api.dev/companies/jazz/catalysts |
| Indications | her2-positive locally advanced or metastatic gea |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### 1H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-02-25.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000009): ""We are pleased with the continued progress of our late-stage pipeline assets, including the recent launch of Ziihera in 2L HER2+ (IHC3+) BTC, upcoming top-line data readout from the HERIZON-GEA-01 trial in 1L GEA, which we now expect in the second half of 2025, and highly encouraging results from the Phase 3 IMforte trial, which we expect to submit as part of an sNDA for Zepzelca® in 1L ES-SCLC in the first half of 2025."" https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001232524-25-000009): ""We are pleased with the continued progress of our late-stage pipeline assets, including the recent launch of Ziihera in 2L HER2+ (IHC3+) BTC, upcoming top-line data readout from the HERIZON-GEA-01 trial in 1L GEA, which we now expect in the second half of 2025, and highly encouraging results from the Phase 3 IMforte trial, which we expect to submit as part of an sNDA for Zepzelca® in 1L ES-SCLC in the first half of 2025."" https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-177505): "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continue to advance our development programs and execute our long-term growth strategy, said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. With recent progress in regulatory approvals for zanidatamab in key international markets, including the U.S., Europe, and China, a much-anticipated, upcoming topline data readout for HERIZON-GEA-01 in the fourth quarter of 2025, and continued progress across our novel, wholly-owned pipeline, we believe Zymeworks is entering a significant period of opportunity for value creation." https://www.sec.gov/Archives/edgar/data/1937653/000119312525177505/d86037dex991.htm

### November 17, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: HER2-positive locally advanced or metastatic GEA.
- First seen 2026-02-24, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001232524-26-000057): "In November 2025, we announced positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial of zanidatamab in combination with chemotherapy, with or without tislelizumab, as first-line treatment for adults with HER2-positive locally advanced or metastatic GEA." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm
- SEC Form 10-Q (accession 0001232524-26-000045): "In November 2025, we announced positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial of zanidatamab in combination with chemotherapy, with or without tislelizumab, as first-line treatment for adults with HER2-positive locally advanced or metastatic GEA." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm
- SEC Form 10-Q (accession 0001232524-26-000025): "In November 2025, we announced positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial of zanidatamab in combination with chemotherapy, with or without tislelizumab, as first-line treatment for adults with HER2-positive locally advanced or metastatic GEA." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000025/jazz-20260331.htm
- SEC Form 10-K (accession 0001232524-26-000013): "In November 2025, we announced positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial of zanidatamab in combination with chemotherapy, with or without tislelizumab, as first-line treatment for adults with HER2-positive locally advanced or metastatic GEA." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm
- SEC Form 10-K (accession 0001628280-26-011946): "On November 17, 2025, we announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive ("HER2+") locally advanced or metastatic gastroesophageal adenocarcinoma ("GEA"), including cancers of the stomach, gastroesophageal junction, and esophagus." https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-17, last confirmed 2025-11-17.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-283887): "This press release contains forward-looking statements, including, but not limited to, statements related to Ziihera's potential as a new standard of care in HER2+ first-line GEA and other HER2-expressing cancers, expected timing of OS data from the pivotal Phase 3 HERIZON-GEA-01, plans to submit a sBLA in first half of 2026 and other statements that are not historical facts." https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-03, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000044): "•Top-line results from the second interim overall survival (OS) analysis for the HERIZON-GEA-01 trial doublet regimen are expected in 3Q26." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm
- Press release filed with the SEC (EX-99) (accession 0001937653-26-000046): "•The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm
- SEC Form 10-Q (accession 0001937653-26-000047): "The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/zyme-20260630.htm

### August 31, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2026-11-05, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001628280-26-070477): "On August 31, 2026, we announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive ("HER2+") locally advanced or metastatic gastroesophageal adenocarcinoma ("GEA")." https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gea-01.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GEA-01 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gea-01

```bibtex
@misc{secapidev_pdufa_gea_01_20261116,
  title        = {GEA-01 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gea-01}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gea_01_20261116","title":"GEA-01 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gea-01","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
